RESEARCH TRIANGLE PARK, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the first quarter 2023.
Recent Highlights
"We are thrilled to report another quarter of strong procedure growth and progress in advancing our mission of Performance-Guided Surgery. The expansion of our pediatric indication into the U.S. is a significant milestone for our company, and we are excited to bring the benefits of our technology to a new patient population. Our continued increase in surgical procedures performed globally is a testament to the value our platform brings to surgeons and patients alike,” said Anthony Fernando, Asensus Surgical President and CEO. “We remain on track to meet our milestones for the year, including the initiation of new Senhance programs, and the achievement of milestones for our LUNA™ Surgical System which is under development. As we look to the future, we remain focused on revolutionizing patient care through innovative surgical technology."
Upcoming 2023 Milestones
For the full year 2023, the Company continues to expect to initiate 10 - 12 new Senhance programs.
During the second half of 2023, the Company continues to expect to achieve the following developmental milestones:
LUNA, the Company’s Next Generation Digital Surgery Platform
Designed based on the feedback received from over 10,000 digital laparoscopic procedures performed with the Senhance System, the LUNA Surgical System is the Company’s next generation digital surgery platform. Through a combination of advanced minimally invasive instrumentation, the first ever digital interface between the surgeon and the console, and industry-leading clinical intelligence tools, we believe the LUNA System is poised to revolutionize the way surgery is performed.
The LUNA System is under development, and not currently available for use.
KARL STORZ Collaboration Agreement
The Company previously announced that it had entered into a Memorandum of Understanding with KARL STORZ VentureONE Pte. Ltd. (KARL STORZ), a new wholly owned subsidiary of KARL STORZ SE & Co. KG. As part of the definitive agreements, KARL STORZ intends to market and sell Asensus’ ISU as a standalone device, and the companies intend to jointly collaborate on the development and integration of next-generation instrumentation. The agreement is progressing towards signing and will represent an important step expanding our commercial reach and development capabilities.
U.S. Pediatric Regulatory Clearance
The Company received U.S. FDA 510(k) clearance for pediatric surgeries in the U.S. during the first quarter of 2023. The Senhance System’s unique combination of 3mm instrumentation with a 5mm camera scope combined with haptic feedback make it a unique robotic assisted laparoscopic solution for pediatric surgeries.
Market Development
Procedure Volumes
During the first quarter of 2023, there was a 20% increase in total surgical procedures completed utilizing the Senhance System over the same period in 2022. Strong utilization patterns brought on by an increased installed base, an increase of new surgeon users at existing installations, and a broader market recovery were the main drivers of this expansion.
2023 Senhance Program Initiations
During the first quarter of 2023, the Company initiated one new Senhance Surgical System placement in Japan.
Clinical Validation
During the quarter, a peer reviewed paper was published highlighting early experience of using the Senhance System in pediatric procedures in the United States. Conducted with IRB approval prior to 510(k) clearance, this study highlights the safety and feasibility of using Senhance System in pediatric cases. The surgical team successfully performed surgeries on eight patients ranging from four months to 16 years old, including procedures such as cholecystectomy, inguinal herniorrhaphy, orchidopexy, and exploration for suspected enteric duplication cyst. The successful use of the Senhance System in pediatric surgeries marks an important milestone for the Company in its ongoing mission to advance the field of surgical robotics.
Intelligent Surgical Unit (ISU) Collects Two Industry Awards on the Heels of Passing 10,000 Procedures on Senhance Surgical System
The Senhance System has passed the 10,000 worldwide procedures milestone and the Company recently received two prestigious industry awards. The first award comes from MedTech Breakthrough, where the ISU was named the "Best New Technology Solution” in the surgical category. This achievement is remarkable as the ISU competed against nearly 4,000 nominations from across the globe. This marks the third time Asensus has earned a MedTech Breakthrough win. The MedTech Breakthrough Awards program is an independent program devoted to honoring excellence in medical and health-related technology companies, products, services and people. The second award comes from Juniper Research's Future Digital Awards for Excellence in Digital Health Innovation, where the ISU has been honored as the "Best Medical Robotics Solution" and awarded the Platinum Winner title. The awards program recognizes organizations that have made outstanding contributions to their industry and are positioned to make a significant impact in the future.
First Quarter Financial Results
For the three months ended March 31, 2023, the Company reported revenue of $1.0 million as compared to revenue of $1.1 million in the three months ended March 31, 2022. Revenue in the first quarter of 2023 included $0.5 million in lease revenue, $0.3 million in instruments and accessories, and $0.2 million in services.
For the three months ended March 31, 2023, total operating expenses were $20.4 million, as compared to $18.2 million, in the three months ended March 31, 2022.
For the three months ended March 31, 2023, net loss was $22.2 million, or $0.09 per share, as compared to a net loss of $19.1 million, or $0.08 per share, in the three months ended March 31, 2022.
Adjusted net loss is a non-GAAP financial measure. See the reconciliation of GAAP to Non-GAAP Measures below. For the three months ended March 31, 2023, the adjusted net loss was $22.0 million, or $0.09 per share, as compared to an adjusted net loss of $16.6 million, or $0.07 per share in the three months ended March 31, 2022, after adjusting for the following charges: amortization of intangible assets, and change in fair value of contingent consideration, both of which are non-cash charges.
Balance Sheet Updates
The Company had cash, cash equivalents, short-term and long-term investments, excluding restricted cash of approximately $57.4 million as of March 31, 2023.
Conference Call
To listen to the conference call on your telephone, please dial 1-844-826-3033 for domestic callers and 1-412-317-5185 for international callers, approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations. The replay will be available on the Company’s website.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of digital laparoscopy and the Senhance Surgical System, the Company is developing the LUNA Surgical System, a next generation robotic and instrument system as a foundation of its digital surgery solution. These systems will be powered by the Intelligent Surgical Unit to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, and digital laparoscopy with the Senhance Surgical System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc
Forward-Looking Statements
This press release includes statements relating to Asensus Surgical, and our 2023 first quarter results. These statements and other statements regarding our future plans and goals constitute "forward looking statements'' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether we will be able to meet our milestones for the year, including the initiation of 10-12 new Senhance programs and the development of the LUNA Surgical System; whether we will meet our 2023 second half milestones of integrated system testing for the LUNA Surgical System, preclinical evaluation for the LUNA Surgical System and Standalone ISU final testing; whether, once fully developed and cleared, the LUNA Surgical System will revolutionize the way surgery is performed; whether the Senhance System’s unique combination of 3mm instrumentation with a 5mm camera scope with haptic feedback make it a unique robotic assisted laparoscopic solution for pediatric surgeries and whether definitive agreements will be successfully negotiated and lead to a successful collaboration between Asensus Surgical and KARL STORZ. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
| Asensus Surgical, Inc. | ||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| (in thousands, except per share amounts) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue: | ||||||||
| Product | $ | 293 | $ | 347 | ||||
| Service | 195 | 308 | ||||||
| Lease | 488 | 411 | ||||||
| Total revenue | 976 | 1,066 | ||||||
| Cost of revenue: | ||||||||
| Product | 1,225 | 375 | ||||||
| Service | 749 | 496 | ||||||
| Lease | 973 | 952 | ||||||
| Total cost of revenue | 2,947 | 1,823 | ||||||
| Gross loss | (1,971 | ) | (757 | ) | ||||
| Operating Expenses: | ||||||||
| Research and development | 10,139 | 6,428 | ||||||
| Sales and marketing | 4,553 | 3,719 | ||||||
| General and administrative | 5,468 | 5,533 | ||||||
| Amortization of intangible assets | 112 | 2,670 | ||||||
| Change in fair value of contingent consideration | 105 | (154 | ) | |||||
| Total Operating Expenses | 20,377 | 18,196 | ||||||
| Operating Loss | (22,348 | ) | (18,953 | ) | ||||
| Other Expense, net: | ||||||||
| Interest income | 439 | 255 | ||||||
| Interest expense | — | (200 | ) | |||||
| Other expense, net | (218 | ) | (146 | ) | ||||
| Total Other Income (Expense), net | 221 | (91 | ) | |||||
| Loss before income taxes | (22,127 | ) | (19,044 | ) | ||||
| Income tax expense | (91 | ) | (84 | ) | ||||
| Net loss | (22,218 | ) | (19,128 | ) | ||||
Comprehensive loss: | ||||||||
| Net loss | (22,218 | ) | (19,128 | ) | ||||
| Foreign currency translation gain (loss) | 550 | (650 | ) | |||||
| Unrealized gain (loss) on available-for-sale investments | 307 | (552 | ) | |||||
| Comprehensive loss | $ | (21,361 | ) | $ | (20,330 | ) | ||
| Net loss per common share attributable to common stockholders – basic and diluted | $ | (0.09 | ) | $ | (0.08 | ) | ||
| Weighted average number of shares used in computing net loss per common share – basic and diluted | 238,280 | 235,892 | ||||||
| Asensus Surgical, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (in thousands, except share amounts) | ||||||||
| (Unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 18,737 | $ | 6,329 | ||||
| Short-term investments, available-for-sale | 37,697 | 64,195 | ||||||
| Accounts receivable, net | 658 | 2,256 | ||||||
| Inventories | 8,844 | 8,284 | ||||||
| Prepaid expenses | 3,326 | 3,584 | ||||||
| Employee retention tax credit receivable | 554 | 554 | ||||||
| Other current assets | 1,740 | 1,671 | ||||||
| Total Current Assets | 71,556 | 86,873 | ||||||
Restricted cash | 1,142 | 1,141 | ||||||
| Long-term investments, available-for-sale | 958 | 3,865 | ||||||
| Inventories, net of current portion | 5,198 | 5,469 | ||||||
| Property and equipment, net | 8,972 | 9,542 | ||||||
| Intellectual property, net | 1,506 | 1,576 | ||||||
| Net deferred tax assets | 171 | 174 | ||||||
| Operating lease right-of-use assets, net | 4,769 | 4,950 | ||||||
| Other long-term assets | 2,251 | 2,463 | ||||||
| Total Assets | $ | 96,523 | $ | 116,053 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 4,972 | $ | 3,348 | ||||
| Accrued employee compensation and benefits | 3,391 | 4,508 | ||||||
| Accrued expenses and other current liabilities | 1,283 | 1,293 | ||||||
| Operating lease liabilities – current portion | 775 | 800 | ||||||
| Deferred revenue | 456 | 465 | ||||||
| Total Current Liabilities | 10,877 | 10,414 | ||||||
| Long Term Liabilities: | ||||||||
| Contingent consideration | 1,361 | 1,256 | ||||||
| Noncurrent operating lease liabilities | 4,568 | 4,738 | ||||||
| Total Liabilities | 16,806 | 16,408 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ Equity | ||||||||
| Common stock $0.001 par value, 750,000,000 shares authorized at March 31, 2023 and December 31, 2022; 239,341,570 and 236,895,440 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 239 | 237 | ||||||
| Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | — | — | ||||||
| Additional paid-in capital | 964,162 | 962,731 | ||||||
| Accumulated deficit | (883,153 | ) | (860,935 | ) | ||||
| Accumulated other comprehensive income | (1,531 | ) | (2,388 | ) | ||||
| Total Stockholders’ Equity | 79,717 | 99,645 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 96,523 | $ | 116,053 | ||||
| Asensus Surgical, Inc. | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (in thousands) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating Activities: | ||||||||
| Net loss | $ | (22,218 | ) | $ | (19,128 | ) | ||
| Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | ||||||||
| Depreciation | 813 | 869 | ||||||
| Amortization of intangible assets | 112 | 2,670 | ||||||
| Amortization of discounts and premiums on investments, net | (89 | ) | 215 | |||||
| Stock-based compensation | 1,916 | 2,245 | ||||||
| Deferred tax expense | 91 | 84 | ||||||
| Bad debt expense | — | 177 | ||||||
| Change in inventory reserves | (374 | ) | (180 | ) | ||||
| Change in fair value of contingent consideration | 105 | (154 | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 1,607 | 25 | ||||||
| Inventories | 203 | (1,440 | ) | |||||
| Operating lease right-of-use assets | 187 | 197 | ||||||
| Prepaid expenses | 250 | 201 | ||||||
| Other current and long-term assets | (27 | ) | (487 | ) | ||||
| Accounts payable | 1,608 | 74 | ||||||
| Accrued employee compensation and benefits | (1,120 | ) | (1,043 | ) | ||||
| Accrued expenses and other current liabilities | (93 | ) | (107 | ) | ||||
| Deferred revenue | (13 | ) | (1 | ) | ||||
| Operating lease liabilities | (206 | ) | (160 | ) | ||||
| Net cash and cash equivalents used in operating activities | (17,248 | ) | (15,943 | ) | ||||
| Investing Activities: | ||||||||
| Purchase of available-for-sale investments | (2,949 | ) | (5,967 | ) | ||||
| Proceeds from maturities of available-for-sale investments | 32,750 | 29,258 | ||||||
| Purchase of property and equipment | (64 | ) | (246 | ) | ||||
| Net cash and cash equivalents provided by investing activities | 29,737 | 23,045 | ||||||
| Financing Activities: | ||||||||
| Taxes paid related to net share settlement of vesting of restricted stock units | (488 | ) | (348 | ) | ||||
| Proceeds from exercise of stock options and warrants | 5 | 12 | ||||||
| Net cash and cash equivalents used in financing activities | (483 | ) | (336 | ) | ||||
| Effect of exchange rate changes on cash and cash equivalents | 403 | (45 | ) | |||||
| Net increase in cash, cash equivalents and restricted cash | 12,409 | 6,721 | ||||||
| Cash, cash equivalents and restricted cash, beginning of period | 7,470 | 19,283 | ||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 19,879 | $ | 26,004 | ||||
| Supplemental Disclosure for Cash Flow Information: | ||||||||
| Cash paid for leases | $ | 330 | $ | 300 | ||||
| Cash paid for taxes | $ | 190 | $ | 29 | ||||
| Supplemental Schedule of Non-cash Investing and Financing Activities: | ||||||||
| Transfer of inventories to property and equipment | $ | 112 | $ | 160 | ||||
| Lease liabilities arising from obtaining right-of-use assets | $ | 45 | $ | — | ||||
| Asensus Surgical, Inc. |
| Reconciliation of Non-GAAP Measures |
| Adjusted Net Loss and Net Loss per Share |
| (in thousands except per share amounts) |
| (Unaudited) |
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2023 | 2022 | ||||||||
| Net loss attributable to common stockholders (GAAP) | $ | (22,218 | ) | $ | (19,128 | ) | |||
| Adjustments | |||||||||
| Amortization of intangible assets | 112 | 2,670 | |||||||
| Change in fair value of contingent consideration | 105 | (154 | ) | ||||||
| Adjusted net loss attributable to common stockholders (Non-GAAP) | $ | (22,001 | ) | $ | (16,612 | ) | |||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2023 | 2022 | ||||||||
| Net loss per share attributable to common stockholders (GAAP) | $ | (0.09 | ) | $ | (0.08 | ) | |||
| Adjustments | |||||||||
| Amortization of intangible assets | — | 0.01 | |||||||
| Change in fair value of contingent consideration | — | — | |||||||
| Adjusted net loss per share attributable to common stockholders (Non-GAAP) | $ | (0.09 | ) | $ | (0.07 | ) | |||
The non-GAAP financial measures for the three months ended March 31, 2023 and 2022, provide management with additional insight into the Company’s results of operations from period to period without non-cash charges, and are calculated using the following adjustments:
a) Intangible assets that are amortized consist of developed technology and purchased patent rights recorded at cost and amortized over 5 to 10 years.
b) Contingent consideration in connection with the acquisition of the Senhance System in 2015 is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, revenue volatility, EURO to USD exchange rate, and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
443-213-0499
MEDIA CONTACT:
Dan Ventresca
Matter Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-874-5488
| Last Trade: | US$0.35 |
| Daily Volume: | 0 |
| Market Cap: | US$94.920M |
August 13, 2024 July 24, 2024 July 23, 2024 July 16, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
